Concurrent with the closing of the transaction, La

Concurrent with the closing of the transaction, Larry Gershman has been appointed as CEO and Chairman of the Board. Gerald Kieft, the Company's prior CEO, will assume the position of CFO and be appointed to the Board of Directors. As part of this acquisition, GelStat has acquired the exclusive rights to multiple products owned by CBD Life Sciences, Inc. The initial marketing efforts will be focused on the re-launch of GelStat Migraine (a patented homeopathic migraine pain reliever) and the initial launch of Chews 2 Lose (an all natural appetite suppressant chewing gum).

Gerald Kieft, GelStat's CFO, said, "Over the past few months, the Company has worked very closely with Mr. Gershman and we are ready to execute our marketing strategy to drive revenue growth. Furthermore, a significant amount of the work had already been completed enabling a rapid start." Mr. Kieft went on to say that, "With the benefit of hindsight, it is clear that Larry is the right person to take GelStat to the next level. His vast knowledge of branding and marketing is without question as well as his understanding of all aspects of our business including product formulations, manufacturing, packaging and distribution."

The Company expects to complete the following milestones within 90 days:

 --  Post financial statements through 9/30/2013 and the required disclosure 
 
    documents to obtain a "Current Pink" status on OTCMarkets.com.  
 
--  Design and develop a new eCommerce website, landing pages and email 
 
    creative for the launch of GelStat Migraine. 
 
--  Test and perfect the new direct response collateral and then launch a 
 
    full scale advertising campaign on GelStat Migraine.  
 
--  Design and develop an eCommerce website, landing pages and email 
 
    creative for the launch of Chews 2 Lose.  
 
--  Test and perfect the new direct response collateral and then launch a 
 
    full scale advertising campaign on Chews 2 Lose.  
 
 
 
 
 
 

Make sure you are first to receive timely information on GelStat Corporation when it hits the newswire. Sign up for GelStat's email news alert system today at:  http://ir.stockpr.com/gelstat/request-information .